Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)

Nobuyuki Katakami; Kazuma Nagata; Akiyoshi Nakakura; Tadashi Okamoto; Toshihiko Kaneda; Masahide Oki; Kana Watanabe; Takaaki Tokito; Yoshihiro Amano; Motohiro Tamiya; Satoshi Morita; Yukimasa Hatachi

doi:10.1093/jjco/hyae132

Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)

Jpn J Clin Oncol. 2024 Sep 23:hyae132. doi: 10.1093/jjco/hyae132. Online ahead of print.

Authors

Nobuyuki Katakami^{1

2

3}, Kazuma Nagata^{2

3}, Akiyoshi Nakakura⁴, Tadashi Okamoto^{1

2

3}, Toshihiko Kaneda⁵, Masahide Oki⁶, Kana Watanabe⁷, Takaaki Tokito⁸, Yoshihiro Amano⁹, Motohiro Tamiya¹⁰, Satoshi Morita⁴, Yukimasa Hatachi¹

Affiliations

¹ Divison of Medical Oncology, Pulmonary Medicine, Takarazuka City Hospital, Takarazuka, Japan.
² Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
³ Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
⁴ Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
⁵ Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
⁶ Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
⁷ Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
⁸ Department of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume, Japan.
⁹ Department of Respiratory Medicine, Shimane University School of Medicine, Izumo, Japan.
¹⁰ Department of Thoracic Malignancy, Osaka Habikino Medical Center, Habikino, Japan.

PMID: 39311098
DOI: 10.1093/jjco/hyae132

Abstract

Background: There is an increased risk of acute exacerbation of idiopathic interstitial pneumonia when treating patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. There is no standard optimal treatment regimen for patients with lung cancer complicated with idiopathic interstitial pneumonia. We aimed to evaluate the efficacy and safety of carboplatin (CBDCA), bevacizumab (Bmab) and weekly paclitaxel (PXT) in patients with idiopathic interstitial pneumonia.

Methods: This phase 2 study involved chemotherapy-naïve patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. Patients received CBDCA (area under the curve: 5 on day 1), PXT (70 mg/m2 on days 1, 8 and 15) and Bmab (15 mg/kg on day 1) every 4 weeks. The primary endpoint was the overall response rate.

Results: Twenty-one patients were enrolled between January 2013 and October 2018 and received at least one course of the protocol treatment. The study was terminated before enrolling the planned number of patients because of poor accrual. The median patient age was 69 (range: 62-79) years, and 19 (90.5%) patients were men. The overall response rate was 61.9% (95% confidence interval [CI], 38.4-81.9), meeting the primary endpoint. The median progression-free survival, time to treatment failure, and overall survival were 9.69 (95% CI, 5.78-11.63), 8.21 (95% CI, 3.75-11.63) and 20.93 (95% CI, 13.17-29.83) months, respectively. There was no acute exacerbation or treatment-related death during protocol treatment.

Conclusion: The results indicate that patients with advanced non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia could be effectively and safely treated using a combination of CBDCA, PXT and Bmab.

Keywords: bevacizumab; chemotherapy; idiopathic interstitial pneumonia; non-small cell non-squamous cell lung cancer; phase II study.

Grants and funding

Kobe City General Hospital Scientific Fund